PDCD1 and lung carcinoma: Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) act to suppress activation of T lymphocytes, and anti-PD-1/PD-L1 therapy has gained great success in the treatment of several solid tumors, such as lung cancer.